South Korea’s Celltrion Inc will begin commercial production of its experimental treatment for COVID-19 this month, as it pushes ahead with clinical trials of the antibody drug.

The company said it planned to make a request soon to regulators for emergency use authorisation of the drug, but that it would start mass production – likely to amount to around one million doses – before receiving that approval.

The treatment became the country’s first COVID-19 antibody drug to be tested on humans after receiving regulatory approval in July for clinical trials.

AlJazeera

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.